NCT03472365View on ClinicalTrials.gov

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

November 25, 2020

Study Completion Date

November 25, 2020

Conditions
Gastric CancerGastroEsophageal Cancer
Interventions
BIOLOGICAL

SHR-1210

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

DRUG

Capecitabine

1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.

DRUG

Oxaliplatin

130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.

DRUG

Apatinib

375 mg administered as continuous oral once daily (QD) of each 3-week cycle.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03472365 - A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter